Gonadotropin‐releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin‐releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study
Authors:
- 1 July 2021
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 81 (12) , 902-912
Abstract
Background: We aimed to determine whether cardiovascular (CV) risk in patients with prostate cancer (PCa) differs between those who receive gonadotropin‐releasing hormone (GnRH) agonist (GnRHa) therapy and those who receive GnRH antagonist therapy.Methods: Using the Taiwan National Health Insurance Research Database, we analyzed data by comparing 666 participants receiving GnRH antagonists and 1332 propensity score‐matched participants treated with GnRHa in a 1:2 fashion during the period from May 1, 2015, to September 30, 2018. Cox proportional‐hazards models were used to estimate the treatment effect on CV outcomes. Furthermore, we conducted an in vitro study to investigate the effect of a GnRHa (leuprolide) or a GnRH antagonist (degarelix) on matrix metalloproteinase‐9 (MMP‐9) expression and invasion ability in THP‐1 differentiated macrophages.Results: GnRH antagonist therapy was associated with a lower risk of composite CV events of myocardial infarction, ischemic stroke, or CV death (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.25–0.90) than GnRHa therapy, with a mean follow‐up period of 1.21 years. Significantly lower risks of CV death (HR, 0.21; 95% CI, 0.06–0.70) and all‐cause mortality (HR, 0.77; 95% CI, 0.61–0.97) were observed in the GnRH antagonist group. In the in vitro study, leuprolide, but not degarelix, significantly increased the expression of MMP‐9 activity and the invasive ability of THP‐1 differentiated macrophages through gelatin zymography and the matrix invasion assay, respectively.Conclusion: GnRH antagonists were associated with reduced risk CV events compared with the GnRHa among patients with PCa, which may be through effects on macrophages.Keywords
Funding Information
- Chang Gung Memorial Hospital, Linkou (CMRPG3H1501, CMRPG3K0031)
This publication has 22 references indexed in Scilit:
- Cilostazol inhibits matrix invasion and modulates the gene expressions of MMP-9 and TIMP-1 in PMA-differentiated THP-1 cellsEuropean Journal of Pharmacology, 2011
- The immune system in atherosclerosisNature Immunology, 2011
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009
- Gonadotropin-Releasing Hormone Modulates Immune System Function via the Nuclear Factor-κB Pathway in Murine Raw264.7 MacrophagesNeuroimmunomodulation, 2009
- Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarctionEuropean Heart Journal, 2008
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- Pathologic assessment of the vulnerable human coronary plaqueHeart, 2004
- Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular DiseaseCirculation, 2003
- AtherosclerosisCell, 2001
- Increased Matrix Metalloproteinase-9 Activity in Unstable Carotid PlaquesStroke, 2000